Navigation Links
Stability Testing Course is Taking the Online Training Format by Storm!
Date:8/12/2011

LONDON, August 12, 2011 /PRNewswire/ --

5 modules - 2 weeks - all recorded to view anytime!

Pharma IQ is delighted to announce that the Stability Testing Online Training Course is proving to be a key event in the pharma industry agendas.


The secret behind the Stability testing Online Training Course success, apart from the course leader - expert Dr. Manuel Zahn, is its user-friendly format which allows flexible and interactive high standard, global training.

This unique interactive online course will focus on:

  • Understanding the Regulatory Aspects of Stability Testing
  • Temperature Monitoring during Shipment
  • Implementing an Effective Stability by Design Programme,
  • The Evaluation of Stability Data and
  • The Stability Testing for Global Markets.

Set to be the "must attend" pharma online training course, Dr. Manuel Zahn will be leading the following organizations through the challenging world of stability testing:


WuXi AppTec, Inc., Dyax Corp, Pfizer Consumer Healthcare, Procter & Gamble, Bristol-Myers Squibb, Pharmascience Inc., Exova, Novartis Consumer Health SA, Novartis, Novartis Pharma AG, Boehringer Ingelheim Chemicals, Beckman Coulter Inc, C. B. Fleet Company, Inc., Norbrook Laboratories Ltd.


The full Stability Testing Online Training Course delegate profile is available here
http://image.exct.net/lib/ff2912787067/d/1/STABILITY%20DELEGATE%20PROFILE.pdf


With 5 interactive modules, an internet-based official exam for additional accreditation and a A-class leading expert, the Stability Testing Online Training Course will arm you with the necessary skills to develop a robust stability testing programme.

Find the full program, event details and registration information on https://www.stabilitytestingonline.com/index.cfm?utm_campaign=PressRelease(paid)&utm_medium=Online&utm_source=&utm_content=Contentled&utm_term=&sid=%%emailaddr%%&mid=%%memberid%%&MAC=20422.001_PPR

or email customerservice@pharma-iq.com


A 10% discount will be available when you mention this press release please email Veronica Araujo (veronica.araujo@iqpc.co.uk) to get more information about this offer.



'/>"/>
SOURCE Pharma IQ
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bristol-Myers Squibb and WuXi PharmaTech Announce Collaboration for a New Analytical and Stability Testing Facility
2. ADVENTRX Announces 9-Month Stability Data Results for ANX-530
3. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
4. Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
5. Stigma Remains a Significant Barrier to Routine HIV Testing by African-American Physicians, Survey Finds
6. Coagulation Self-Testing: Devices, Markets, Players and Prospects
7. Magellans Dynex® Agility™ ELISA Processor Dramatically Reduces Laboratory Time and Labor in Diagnostic Testing While Ensuring the Most-Accurate Results
8. Clearbridge BioLoc Unveils Innovative Lab-on-Card Analysis Platform for Point-of-Care Testing at Worlds Largest Clinical Lab Conference
9. Genetic Testing Can Help the US Cut Costs and Improve Health Care
10. TPI Ships Macrolide API Samples for International Sales Standard Testing
11. Microtest Laboratories Announces New Fast-Track Toxicity Testing for Medical Devices Using Zebrafish Embryos
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
(Date:5/18/2017)... -- Bayer announced today that the latest research from across ... 53 rd Annual Meeting of the American Society ... Chicago . The ... and thyroid cancers, as well as lymphomas, and includes ... of copanlisib in patients with relapsed or refractory follicular ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
Breaking Medicine Technology:
(Date:5/24/2017)... , ... May 24, 2017 , ... ... of ExtraHop to its solutions portfolio. ExtraHop delivers an analytics-first approach, layered with ... every IT system, from the datacenter to the cloud to the edge. Through ...
(Date:5/24/2017)... ... 24, 2017 , ... The CFOs included on this list ... in the nation and help their organizations navigate the challenges in healthcare today. ... in developing successful hospital and health system strategy. , Becker's Hospital Review has ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International (MDLand), a ... today that its iClinic V12.2 solution has achieved approval from National Center for ... PCMH 2017 standards which emphasize team-based care with a significant focus on the ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, May ... since 2009, according to a Workers Compensation Research Institute (WCRI) study, a contrast ... North Carolina System: CompScope™ Benchmarks, 17th Edition looks at indemnity and medical ...
(Date:5/23/2017)... ... 2017 , ... London, May 23, 2017: Walter Schindler, the Founder and Managing ... Guest Speaker and Contributor to a weeklong series of classes, meetings, field trips and ... , Walter Schindler and SAIL Capital have received an increasing number ...
Breaking Medicine News(10 mins):